These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 32415074)

  • 41. In-depth phylogenetic analysis of the hemagglutinin gene of influenza A(H3N2) viruses circulating during the 2016-2017 season revealed egg-adaptive mutations of vaccine strains.
    Galli C; Orsi A; Pariani E; Lai PL; Guarona G; Pellegrinelli L; Ebranati E; Icardi G; Panatto D
    Expert Rev Vaccines; 2020 Jan; 19(1):115-122. PubMed ID: 31875483
    [No Abstract]   [Full Text] [Related]  

  • 42. Development of a Pan-H1 Influenza Vaccine.
    Darricarrère N; Pougatcheva S; Duan X; Rudicell RS; Chou TH; DiNapoli J; Ross TM; Alefantis T; Vogel TU; Kleanthous H; Wei CJ; Nabel GJ
    J Virol; 2018 Nov; 92(22):. PubMed ID: 30185594
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Monoclonal antibodies with high virus-neutralizing activity against pandemic influenza virus A/llV-Moscow/01/2009 (H1N1)swl].
    Klimova RR; Masalova OV; Burtseva EI; Chichev EV; Lesnova EI; Oskerko TA; Mukasheva EA; Rudneva IA; Lvov DK; Kushch AA
    Vopr Virusol; 2011; 56(3):15-20. PubMed ID: 21786621
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity.
    Belshe RB; Coelingh K; Ambrose CS; Woo JC; Wu X
    Vaccine; 2010 Feb; 28(9):2149-56. PubMed ID: 20003926
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.
    Boonnak K; Matsuoka Y; Wang W; Suguitan AL; Chen Z; Paskel M; Baz M; Moore I; Jin H; Subbarao K
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28490598
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain.
    Raymond DD; Stewart SM; Lee J; Ferdman J; Bajic G; Do KT; Ernandes MJ; Suphaphiphat P; Settembre EC; Dormitzer PR; Del Giudice G; Finco O; Kang TH; Ippolito GC; Georgiou G; Kepler TB; Haynes BF; Moody MA; Liao HX; Schmidt AG; Harrison SC
    Nat Med; 2016 Dec; 22(12):1465-1469. PubMed ID: 27820604
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of key amino acid substitutions in the hemagglutinin of influenza A (H3N2) viruses on vaccine production and antibody response.
    Chen Z; Zhou H; Jin H
    Vaccine; 2010 May; 28(24):4079-85. PubMed ID: 20399830
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protection of guinea pigs by vaccination with a recombinant swinepox virus co-expressing HA1 genes of swine H1N1 and H3N2 influenza viruses.
    Xu J; Yang D; Huang D; Xu J; Liu S; Lin H; Zhu H; Liu B; Lu C
    Arch Virol; 2013 Mar; 158(3):629-37. PubMed ID: 23135159
    [TBL] [Abstract][Full Text] [Related]  

  • 49. H3N2 influenza viruses in humans: Viral mechanisms, evolution, and evaluation.
    Allen JD; Ross TM
    Hum Vaccin Immunother; 2018; 14(8):1840-1847. PubMed ID: 29641358
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Addition of N-glycosylation sites on the globular head of the H5 hemagglutinin induces the escape of highly pathogenic avian influenza A H5N1 viruses from vaccine-induced immunity.
    Hervé PL; Lorin V; Jouvion G; Da Costa B; Escriou N
    Virology; 2015 Dec; 486():134-45. PubMed ID: 26433051
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preventing an Antigenically Disruptive Mutation in Egg-Based H3N2 Seasonal Influenza Vaccines by Mutational Incompatibility.
    Wu NC; Lv H; Thompson AJ; Wu DC; Ng WWS; Kadam RU; Lin CW; Nycholat CM; McBride R; Liang W; Paulson JC; Mok CKP; Wilson IA
    Cell Host Microbe; 2019 Jun; 25(6):836-844.e5. PubMed ID: 31151913
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly.
    de Jong JC; Beyer WE; Palache AM; Rimmelzwaan GF; Osterhaus AD
    J Med Virol; 2000 May; 61(1):94-9. PubMed ID: 10745239
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of Hemagglutinin Residues Responsible for H3N2 Antigenic Drift during the 2014-2015 Influenza Season.
    Chambers BS; Parkhouse K; Ross TM; Alby K; Hensley SE
    Cell Rep; 2015 Jul; 12(1):1-6. PubMed ID: 26119736
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets.
    Baz M; Paskel M; Matsuoka Y; Zengel JR; Cheng X; Treanor JJ; Jin H; Subbarao K
    J Virol; 2015 Jul; 89(13):6907-17. PubMed ID: 25903333
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Canine H3N8 influenza vaccines partially protect mice against the canine H3N2 strain currently circulating in the United States.
    Willis E; Parkhouse K; Krammer F; Hensley SE
    Vaccine; 2016 Nov; 34(46):5483-5487. PubMed ID: 27670073
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antigenic Pressure on H3N2 Influenza Virus Drift Strains Imposes Constraints on Binding to Sialylated Receptors but Not Phosphorylated Glycans.
    Byrd-Leotis L; Gao C; Jia N; Mehta AY; Trost J; Cummings SF; Heimburg-Molinaro J; Cummings RD; Steinhauer DA
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31484755
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.
    Ansaldi F; Canepa P; Ceravolo A; Valle L; de Florentiis D; Oomen R; Vogel FR; Denis M; Samson SI; Icardi G
    Vaccine; 2012 Apr; 30(18):2908-13. PubMed ID: 22342501
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.
    Carter DM; Darby CA; Lefoley BC; Crevar CJ; Alefantis T; Oomen R; Anderson SF; Strugnell T; Cortés-Garcia G; Vogel TU; Parrington M; Kleanthous H; Ross TM
    J Virol; 2016 May; 90(9):4720-4734. PubMed ID: 26912624
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biochemistry. Catching a moving target.
    Wang TT; Palese P
    Science; 2011 Aug; 333(6044):834-5. PubMed ID: 21836007
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.